Healthcare
Australian VCs invest $16m in domestic drug developer
Australian VC investors Brandon Capital and Uniseed have committed $16 million to Que Oncology, a clinical-stage drug development company established by the University of Queensland (UQ) and US-based Emory University.
Fund focus: Lyfe attracts a diversified following for Fund II
Having been supported by fund-of-funds when raising its first China healthcare vehicle, Lyfe Capital has added pension funds, endowments and family offices to its $420 million second fund
OneVentures invests $7.4m in Australia's Prota Therapeutics
Australia’s OneVentures has invested A$10 million ($7.4 million) in Prota Therapeutics, a domestic immunotherapy technology developer aiming to commercialize new peanut allergy treatments for children.
Deal focus: Quadrant cashes in on Icon's growth potential
Quadrant Private Equity agrees a $746 million exit from Icon Group, with new owners QIC, Goldman Sachs and Pagoda Investment keen to continue the cancer specialist's expansion in Asia
OrbiMed leads $19m round for Sino-US drug developer
OrbiMed Asia Partners has led a $19 million Series B round of funding for InventisBio, a pharmaceutical developer based in Shanghai with operations in China and the US.
China's Lyfe Capital raises $420m for second healthcare fund
China-based healthcare specialist Lyfe Capital has raised more than $420 million for its second fund, which comprises parallel US dollar and renminbi-denominated tranches.
Australia's Saluda Medical secures $40m round
Action Potential Venture Capital (APVC), an investment arm of British pharmaceutical company GlaxoSmithKline, has led a A$53 million ($40 million) all-equity Series D round for Australia’s Saluda Medical.
China genomics: Coded messages
Investors are looking to tap the massive potential of China’s genomic industry, with a particular focus on companies that leverage large amounts of patient data to support drug development and testing services
CITIC Capital in $600m Australian health acquisition
CITIC Capital China has joined a consortium including China’s Humanwell Healthcare to acquire the sexual health division of Australia-listed medical products supplier Ansell for $600 million.
China biopharma player gets $25m Series B
CANbridge Life Science, a Beijing-based clinical-stage biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has raised a Series B round worth $25 million.
Blue Sky exits Australia's HPS via $116m trade sale
Blue Sky Alternative Investors will exit its stake in HPS, Australia’s largest provider of outsourced pharmacy services to hospitals, as healthcare business EBOS agreed to buy the asset for A$154 million ($116 million).
Sino-Australian consortium to buy Icon Group from Quadrant
QIC, Goldman Sachs and Pagoda Investment – a China-focused private equity firm set up by a former QIC executive – have agreed to buy Icon Group, an Australian oncology services provider, from Quadrant Private Equity.
Frontline BioVentures merges with WuXi Ventures
Chinese healthcare specialists Frontline BioVentures and WuXi Healthcare Ventures have merged, forming a new investment firm called 6 Dimensions Capital.
CDH-backed Zhenghai Bio-tech jumps on Shenzhen debut
Yantai Zhenghai Bio-tech, a Chinese biotechnology company backed by CDH Investments, saw its stock gain 44.03% on its first day of trading following a RMB234 million ($34 million) IPO in Shenzhen.
IFC proposes $75m investment in India's Max Healthcare
The International Finance Corporation (IFC), the investment arm of the World Bank, is considering an investment of up to $75 million in Indian hospital chain Max Healthcare.
Highland closes Asia, US healthcare fund at $147m
Highland Capital Management has raised approximately $147 million for an Asia and North America-focused healthcare fund, having received an anchor LP commitment from South Korea’s National Pension Service (NPS).
IFC to exit India's Max Healthcare for $66m
The International Finance Corporation (IFC), the investment arm of the World Bank, will exit its entire stake in Indian hospital chain Max Healthcare for INR4.2 billion ($65.6 million).
Hong Kong's AID Partners buys Israel's GeneSort
Hong Kong-listed private equity firm AID Partners has acquired Israel-based molecular diagnostics company GeneSort for $23 million.
Deal focus: WuXi NextCode eyes mass-market genomics
By acquiring NextCode Health in 2015, WuXi Pharmatech combined its gene sequencing capabilities with one of the world's largest genome datasets. PE investors are backing the business to sell genomic testing services to Chinese patients
VCs back South Korean biopharma player ExoCoBio
South Korean biopharmaceutical developer ExoCoBio has raised an $11 million Series A round from investors including SBI Investment, Atinum Investment, ID Ventures, and Dt&Investment.
China's Ping An to launch $1b global fintech, healthcare fund
China’s Ping An Insurance is launching a $1 billion fund that will make financial technology and healthcare investments globally as the company looks to establish a footprint beyond its home market.
Temasek, Yunfeng lead $75m round for contract genomics player
Temasek Holdings and Chinese PE firm Yunfeng Capital have jointly led a $75 million Series B round for Wuxi NextCode, a genome sequencing analysis subsidiary of China-based contract research organization (CRO) WuXi PharmaTech.
Singapore government launches $716m PE fund
The Singapore government and domestic GP Makara Capital have launched a S$1 billion ($716 million) private equity fund that will focus on intellectual property (IP)-driven companies.
KV Asia exits Singapore nursing home business
KV Asia Capital has exited its 100% interest in Singaporean nursing home services provider Orange Valley Healthcare to a local media company for about S$164 million ($117.5 million).